CapsoVision, Inc. (CV)
| Market Cap | 307.79M +70.9% |
| Revenue (ttm) | 13.89M +11.0% |
| Net Income | -29.83M |
| EPS | -0.62 |
| Shares Out | 50.05M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 150,807 |
| Open | 6.40 |
| Previous Close | 6.45 |
| Day's Range | 6.03 - 6.52 |
| 52-Week Range | 3.43 - 15.37 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2026 |
About CV
CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It also provides CapsoCloud cloud-based software-as-a-service ecosystem as a... [Read more]
Financial Performance
In 2025, CapsoVision's revenue was $13.55 million, an increase of 15.29% compared to the previous year's $11.76 million. Losses were -$25.32 million, 27.2% more than in 2024.
Financial StatementsNews
CapsoVision files $250M mixed securities shelf
16:49 EDT CapsoVision (CV) files $250M mixed securities shelf
CapsoVision Earnings Call Transcript: Q2 2026
Q2 2026 saw 10% revenue growth and strong adoption of CapsoCam Plus, with over 176,000 patients imaged and a successful international launch of AI Highlights. Gross margin declined due to pricing and tariff pressures, but commercial momentum and pipeline progress remain strong.
CapsoVision Earnings release: Q2 2026
CapsoVision released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
CapsoVision Quarterly report: Q2 2026
CapsoVision has published its Q2 2026 quarterly earnings report on August 13, 2026.
CapsoVision Reports Second Quarter 2026 Financial Results
SARATOGA, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions...
CapsoVision Registration statement: Registration filing
CapsoVision filed a registration statement on August 13, 2026, providing details about a securities offering with the SEC.
CapsoVision® Announces International Launch of AI Highlights
AI-assisted review feature designed to support physician review of small bowel capsule endoscopy studies using the CapsoCam Plus® system AI-assisted review feature designed to support physician review...
CapsoVision to Release Second Quarter 2026 Financial Results on August 13, 2026
SARATOGA, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions...
CapsoVision Appoints Gastroenterology Leader David S. Shields, M.D.
SARATOGA, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (Nasdaq: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions...
CapsoVision Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and reaffirmed governance commitments. All proposals passed, with final results to be filed in a Form 8-K. No shareholder questions were raised.
CapsoVision Earnings Call Transcript: Q1 2026
Revenue remained stable at $2.8M in Q1 2026, with strong utilization and expanding clinical adoption. AI-assisted capabilities are on track for mid-year launch, and a $14M private placement bolstered the balance sheet.
CapsoVision Earnings release: Q1 2026
CapsoVision released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
CapsoVision Quarterly report: Q1 2026
CapsoVision has published its Q1 2026 quarterly earnings report on May 14, 2026.
CapsoVision Reports First Quarter 2026 Financial Results
SARATOGA, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions,...
CapsoVision to Release First Quarter 2026 Financial Results on May 14, 2026
SARATOGA, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solution...
CapsoVision Proxy statement: Proxy filing
CapsoVision filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
CapsoVision files to sell 2.87M shares of common stock for holders
16:39 EDT CapsoVision (CV) files to sell 2.87M shares of common stock for holders
CapsoVision Registration statement: Registration filing
CapsoVision filed a registration statement on April 17, 2026, providing details about a securities offering with the SEC.
CapsoVision price target lowered to $10 from $14 at Benchmark
Benchmark analyst Bruce Jackson lowered the firm’s price target on CapsoVision (CV) to $10 from $14 and keeps a Speculative Buy rating on the shares after the company reported Q4…
CapsoVision Earnings Call Transcript: Q4 2025
Revenue grew 15% year-over-year in 2025, driven by CapsoCam Plus adoption and new account growth. AI-enabled product pipeline advanced, with pivotal studies and regulatory submissions on track. Balance sheet strengthened by $14 million equity raise.
CapsoVision Annual report: Q4 2025
CapsoVision has published its Q4 2025 annual report on March 26, 2026.
CapsoVision Earnings release: Q4 2025
CapsoVision released its Q4 2025 earnings on March 26, 2026, summarizing the period's financial results.
CapsoVision Slides: Corporate presentation
CapsoVision has posted slides in relation to its latest quarterly earnings report, which was published on March 26, 2026.
CapsoVision price target raised to $11 from $7 at Roth Capital
Roth Capital raised the firm’s price target on CapsoVision (CV) to $11 from $7 and keeps a Buy rating on the shares after its Q4 pre-announcement and the closing of…
CapsoVision Transcript: The 38th Annual Roth Conference
CapsoVision highlighted its AI-powered capsule endoscopy platform, targeting major GI markets with a robust pipeline for colon, pancreas, esophagus, and stomach imaging. Strategic partnerships and recent financing support expansion and R&D through 2026.